Theo Outlook
GE HealthCare Technologies (GEHC) presents a compelling bullish case as a leading medical technology provider trading at a trailing P/E of 15.22 and forward P/E of 13.74, below sector averages for growth potential. With a $31.6B market cap, TTM revenue of $20.6B showing 7.1% quarterly growth, and diluted EPS of $4.55, shares at ~$69.23 appear undervalued amid positive analyst sentiment.
Key catalysts include a $93.47 analyst target (35% upside), with 3 strong buys and 11 buys among 21 ratings. Growth drivers feature demand for imaging, diagnostics, and digital solutions, plus upcoming Q1 2026 earnings on April 29 estimating $1.07 EPS, potentially reigniting momentum post recent dip.
Risks encompass -17.7% quarterly earnings growth, medtech competition, and 1.18 beta exposing to market swings. Mitigate via 22.4% ROE, 93.4% institutional ownership, and 0.2% dividend yield; diversify and focus long-term on healthcare tailwinds.
Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.